Experience with Octreotide in patients with castration refractory prostate cancer

被引：0
|
作者：
Ganov, D. I. [1 ]
Varlamov, S. A. [1 ]
机构：
[1] Altai State Med Univ, Kussian Acad Med Sci, NN Blokhin Russian Canc Res Ctr, Altai Branch, Barnaul, Russia
来源：
ONKOUROLOGIYA | 2011年 / 7卷 / 04期
关键词：
castration refractory prostate cancer; sustained-release octreotide;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Fifteen patients with castration refractory prostate cancer have been treated with sustained-release octreotide in combination with dexamethasone at the Altai Territory Oncology Dispensary since 2008. Control PSA test revealed that 9 (60 %) patients had positive changes; tumor process stabilization was noted in 4 (26.7 %) and only 2 (13.3 %) were found to have disease progression. Thus, more than 86 % of patients responded to combination treatment with sustained-release octreotide + dexamethasone. Octreotide treatment caused no serious specific adverse toxic reactions.
引用
收藏
页码：71 / 73
页数：3
相关论文
共 50 条
  • [1] Experience with octreotide depot in the treatment of castration-resistant prostate cancer
    Kolesnikov, G. P.
    ONKOUROLOGIYA, 2015, 11 (02): : 85 - 88
  • [2] Treatment of castration refractory Prostate cancer
    Rauchenwald, Michael
    Bauernhofer, Thomas
    De Santis, Maria
    Fuereder, Thorsten
    Hoeltl, Wolfgang
    Kramer, Gero
    Krause, Steffen
    Loidl, Wolfgang
    Oismueller, Renee
    Reissigl, Andreas
    Schmeller, Nikolaus
    Stackl, Walter
    Stoiber, Franz
    Krainer, Michael
    WIENER KLINISCHE WOCHENSCHRIFT, 2012, 124 (15-16) : 538 - 551
  • [3] Octreotide in the management of hormone-refractory prostate cancer
    Vainas, IG
    CHEMOTHERAPY, 2001, 47 : 109 - 126
  • [4] Surgical Castration in Hormone-Refractory Metastatic Prostate Cancer Patients Can Be an Alternative for Medical Castration
    Zaitsu, Masayoshi
    Yamanoi, Mariko
    Mikami, Koji
    Takeshima, Yuta
    Okamoto, Naohiko
    Imao, Sadao
    Tonooka, Akiko
    Takeuchi, Takumi
    ADVANCES IN UROLOGY, 2012, 2012
  • [5] Radium-223 dichloride in patients with castration-refractory prostate cancer
    Winter, B. M.
    von Rundstedt, F. -C.
    Grimm, M. -O.
    UROLOGE, 2017, 56 (11): : 1435 - 1439
  • [6] Prognostic and predictive clinical factors for progression to castration refractory prostate cancer in patients with hormone sensitive prostate cancer
    Watanabe, M.
    Kanao, K.
    Sugie, M.
    Morinaga, S.
    Muramatsu, H.
    Kobayashi, I.
    Kajikawa, K.
    Nishikawa, G.
    Zennami, K.
    Nakamura, K.
    Sumitomo, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 73 - 73
  • [7] Experience with fulvestrant acetate in castration-resistant prostate cancer patients
    Gasent Blesa, J. M.
    Alberola Candel, V.
    Giner Marco, V.
    Giner-Bosch, V.
    Provencio Pulla, M.
    Laforga Canales, J. B.
    ANNALS OF ONCOLOGY, 2010, 21 (05) : 1131 - 1132
  • [8] Initial experience with abiraterone acetate in patients with castration-resistant prostate cancer
    Beardo-Villar, P.
    Ledo-Cepero, M. J.
    Gavira-Moreno, R.
    Soto-Delgado, M.
    Soto-Vittalba, J.
    Alvarez-Ossorio, J. L.
    Juarez-Soto, A.
    ACTAS UROLOGICAS ESPANOLAS, 2014, 38 (05): : 339 - 345
  • [9] Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience
    Kazuhiko Nakano
    Shigeyuki Ohta
    Kenji Komatsu
    Taro Kubo
    Akinori Nukui
    Kazumi Suzuki
    Shinsuke Kurokawa
    Minoru Kobayashi
    Tatsuo Morita
    BMC Urology, 12
  • [10] Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience
    Nakano, Kazuhiko
    Ohta, Shigeyuki
    Komatsu, Kenji
    Kubo, Taro
    Nukui, Akinori
    Suzuki, Kazumi
    Kurokawa, Shinsuke
    Kobayashi, Minoru
    Morita, Tatsuo
    BMC UROLOGY, 2012, 12
12345